FDA Requires GLP-1 Drug Eye Risk Warnings

Agency will add nonarteritic anterior ischemic optic neuropathy risk information to labeling for all GLP-1 receptor agonists.

Updated on Nov. 9, 2026 in Diabetes

Bold vector editorial illustration of an injectable pen-style medication device beside folded cream paper and an amber dropper on a plain surface. — The Food and Drug Administration on Tuesday ordered makers of all GLP-1 receptor agonist drugs to add a warning about rare vision loss called NAION to their labels. AI Illustration. Upload story photo >

The Food and Drug Administration is requiring application holders to add information about nonarteritic anterior ischemic optic neuropathy (NAION), a rare form of vision loss, to the Warnings and Precautions section of labeling for all GLP-1 receptor agonists. NAION cases have been reported for every currently marketed product in the class.

Why it matters

The label change reflects an FDA review of adverse event reports, a meta-analysis of 126 clinical trials, and an observational cohort study, all of which pointed to a possible safety signal for patients taking these widely prescribed diabetes and weight-management drugs. Clinicians and patients in the United States will see the updated warning in product labeling.

The FDA meta-analysis covered 126 GLP-1 RA trials with 134,253 patients and identified 15 probable NAION events, with an incidence of 6.4 per 100,000 person-years in treated patients versus 3.8 in comparators. Whether the excess reflects a true drug effect remains unresolved, since the number of events is small and no mechanism was identified in animal studies.

The players

Food and Drug Administration

The U.S. federal agency responsible for regulating drug labeling and post-market safety monitoring, which issued the requirement.

Hathaway et al.

Authors of a July 2024 published article reporting increased NAION risk with semaglutide, which prompted the FDA's further assessment.

The details

The FDA reviewed adverse event reports from its monitoring system, a meta-analysis of trial data, and a retrospective cohort study in the Sentinel network covering 2019 to 2024. The agency said published observational studies consistently reported increased NAION risk with GLP-1 RAs compared with DPP-4 or SGLT-2 inhibitors, prompting the labeling action.

July 2024: Hathaway et al. published an article on NAION risk with semaglutide, prompting further FDA assessment.
2019 to 2024: Period covered by the Sentinel cohort study of adults with type 2 diabetes.
November 9, 2026: FDA published the safety labeling change requirement.

Health Landscape

The labeling action follows the FDA Sentinel system's role in post-market surveillance, which used real-world claims data from 2019 to 2024 to test NAION risk across GLP-1 RAs against DPP-4 and SGLT-2 inhibitors. The result places this class-wide warning alongside earlier cases where observational data prompted label revisions for widely used diabetes therapies.

Patients taking any GLP-1 receptor agonist should discuss the new NAION warning with their prescriber, especially if they notice sudden vision changes. The updated label will appear in product information for all currently marketed drugs in this class.

The takeaway

Anyone taking a GLP-1 receptor agonist should know the warning exists and report any sudden vision loss to a doctor promptly. Discussing both the benefits and this rare risk with a prescriber helps patients make informed decisions about continued treatment.